慢性血栓栓塞性肺高血压患者的肝脏功能障碍
Athiththan Yogeswaran1, Daniel Zedler1, Manuel J Richter1
1Department of Internal Medicine, Member of the German Center for Lung Research (DZL), Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany.
Frontiers in medicine
|August 7, 2023
概括
慢性血栓栓塞性肺高血压 (CTEPH) 中的肝功能障碍与静脉堵塞有关,而不是心力衰竭. 末期肝病模型 (MELDNa) 评分可以识别风险较高的CTEPH患者.
科学领域:
- 心脏病学 心脏病学
- 肝病学 肝病学是一种肝病学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 心脏与肝脏和脏的相互作用在心血管疾病中已知.
- 在慢性血栓栓塞性肺高血压 (CTEPH) 中肝功能障碍的临床意义尚不清楚.
- 这项研究调查了CTEPH患者肝功能障碍和心脏功能/存活率之间的关联.
研究的目的:
- 为了确定肝功能障碍与右心功能之间的关联,通过末期肝病模型 (MELDNa) 评分进行测量.
- 评估MELDNa得分和CTEPH患者的存活率之间的关系.
- 阐明CTEPH中肝功能障碍的潜在机制.
主要方法:
- 来自吉森肺高血压登记处的患者分析,可用MELDNa得分,不包括那些服用维生素K对抗剂的患者.
- 计算MELDNa得分,使用基于MELD得分,血清,肌素,胆红素和国际标准化比率的既定公式.
- 相关性和回归分析以确定与MELDNa相关的因素及其对死亡率的预测值.
主要成果:
- 包括72名CTEPH患者 (74%为女性),中位数MELDNa得分为9.
- 梅尔德纳分数与右心房和心室功能以及肺血液动力学有显著的相关性.
- 肝功能障碍,由右心房应变和三腹吐驱动,预测了基线和随访时的死亡率.
结论:
- 在CTEPH中,肝功能障碍主要与静脉拥堵有关,而不是心脏前置衰竭.
- 梅尔德纳分数作为一种简单而有效的替代标记,用于识别有风险的CTEPH患者.
- 在基线和后续评估中,MELDNa可以帮助风险分层.
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Pulmonary Embolism III: Nursing Management
15
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
15
Pulmonary Hypertension: Classification and Pathogenesis
223
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
223
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Pulmonary Embolism I: Introduction
7
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
7
Renal Failure: Dose Adjustments
122
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
122


